What are the benefits and risks of dual antiplatelet treatment for acute minor ischemic stroke or high risk transient ischemic attack?

BEEM Bottom Line

Why is this study important?

Current guidelines recommend antiplatelet therapy in the management of acute ischemic stroke and transient ischemic attack (TIA), most commonly aspirin (ASA) alone. In this systematic review and meta-analysis of the literature to date, the benefits and safety of clopidogrel and ASA versus ASA alone have been demonstrated. These findings strongly suggest that dual antiplatelet therapy (DAPT) should be used for these patients and that clinical guidelines should reflect this new evidence.

Which, if any, threats to validity are most likely to have an impact on the results and how?

Thank you for your interest in the BEEM Journal!

To read the rest of this article or to access the entire collection of BEEM Critical Appraisals, please purchase a subscription at the link below.

If you would like a pre-view, click here to view some sample articles

Premium Content Available Through Subscription

BEEM is a knowledge translation project which aims to extract the most recent, EM relevant, and valid evidence from the volumes of available medical research and deliver it to EM practitioners in an easily consumable format to help guide their clinical practice. This valuable distilled information provided by BEEM is available through BEEM's accredited CME courses or through our online journal.

A BEEM Journal Subscription will provide you with unlimited access to our entire collection of Critical Appraisals for 1 year.